Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol by Eccles, Diana et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Cancer
Open Access Study protocol
Prospective study of Outcomes in Sporadic versus Hereditary 
breast cancer (POSH): study protocol
Diana Eccles*1, Sue Gerty1, Peter Simmonds1, Victoria Hammond1, 
Sarah Ennis1, Douglas G Altman2 and the POSH steering group3
Address: 1Somers Cancer Sciences Building Mail Point 824, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 
6YA, UK, 2Centre for Statistics in Medicine, Wolfson College Annexe, Linton Road, Oxford OX2 6UD, UK and 3POSH Steering group: see after 
acknowledgement section for members and roles
Email: Diana Eccles* - de1@soton.ac.uk; Sue Gerty - S.M.Gerty@soton.ac.uk; Peter Simmonds - P.D.Simmonds@soton.ac.uk; 
Victoria Hammond - vnh@soton.ac.uk; Sarah Ennis - S.Ennis@soton.ac.uk; Douglas G Altman - doug.altman@cancer.org.uk; the POSH steering 
group - de1@soton.ac.uk
* Corresponding author    
Abstract
Background: Young women presenting with breast cancer are more likely to have a genetic
predisposition to the disease than breast cancer patients in general. A genetic predisposition is
known to increase the risk of new primary breast (and other) cancers. It is unclear from the
literature whether genetic status should be taken into consideration when planning adjuvant
treatment in a young woman presenting with a first primary breast cancer. The primary aim of the
POSH study is to establish whether genetic status influences the prognosis of primary breast cancer
independently of known prognostic factors.
Methods/design: The study is a prospective cohort study recruiting 3,000 women aged 40 years
or younger at breast cancer diagnosis; the recruiting period covers 1st June 2001 to 31st December
2007. Written informed consent is obtained at study entry. Family history and known
epidemiological risk data are collected by questionnaire. Clinical information about diagnosis,
treatment and clinical course is collected and blood is stored. Follow up data are collected annually
after the first year. An additional recruitment category includes women aged 41 to 50 years who
are found to be BRCA1 or BRCA2 gene carriers and were diagnosed with their first breast cancer
during the study recruiting period.
Discussion: Power estimates were based on 10% of the cohort carrying a BRCA1 gene mutation.
Preliminary BRCA1 and BRCA2 mutation analysis in a pilot set of study participants confirms we
should have 97% power to detect a difference of 10% in event rates between gene carriers and
sporadic young onset cases. Most of the recruited patients (>80%) receive an anthracycline
containing adjuvant chemotherapy regimen making planned analyses more straightforward.
Background
Less than 5% of breast cancers diagnosed in the UK are
diagnosed in women aged 40 years or younger although
there is a rapid increase in the incidence from about 35
years of age[1].
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Published retrospective studies suggest that early age at
onset of breast cancer (below 35 years) is a poor prognosis
factor; high grade and oestrogen receptor (ER) negative
tumours appear to be more frequent in younger
women[2,3]. Breast cancer arising due to a high pene-
trance genetic predisposition gene such as BRCA1 or
BRCA2 occurs at younger average age than breast cancer in
the general population and a higher proportion of young
onset cases will have a genetic predisposition than breast
cancer cases in general. Family history is still the most
important indicator of an underlying inherited predispo-
sition [4]. However BRCA1 and BRCA2 may account for
less than 40% of all familial breast cancer; multiple low
penetrance breast cancer predisposition genes are likely to
account for the rest[5]. These low penetrance alleles are
now beginning to be discovered through both candidate
gene approaches and whole genome SNP (single nucle-
otide polymorphism) analyses [6-9].
Certain tumour characteristics are characteristically seen
in breast cancers due to a BRCA1 gene mutation and also
to a lesser degree in BRCA2 gene carriers [10-12]. For
example high grade, ER, PR and HER2 negative tumours
are significantly more frequent in BRCA1 gene carriers
than in breast cancers in none gene carriers. In examining
the effect of BRCA1 or BRCA2 status on prognosis after
breast cancer diagnosis, it is important in comparing
genetic with apparently sporadic breast cancer cases, to
take into account known prognostically important
tumour characteristics and adjuvant treatment regimens
should be broadly similar in the groups being compared.
There are several areas of important clinical uncertainty
regarding the management of hereditary breast cancer. It
is not clear whether the prognosis for women with BRCA1
and BRCA2 related breast cancers differs compared to spo-
radic tumours with similar pathological prognostic indi-
ces. Current publications variously suggest that overall
survival for BRCA1 gene carriers is better[13,14], the
same[15,15,16] or much worse[17,18] than sporadic can-
cers but most published studies to date have been based
on small numbers and retrospective data and are inher-
ently unreliable.
Both BRCA1 and BRCA2 are involved in cellular DNA
repair mechanisms [19]. Furthermore a number of other
genes involved in DNA repair and found to be mutated at
low frequencies in the general population (<5%) are cur-
rently implicated as low penetrance susceptibility alleles
[6,7,20]. This, at least hypothetically and perhaps contro-
versially, might raise some concerns about the use of
mammographic screening in those at increased risk. This
may also have relevance for gene carriers undergoing
potentially curative treatment for early stage breast cancer
since radiation therapy and chemotherapy will induce
DNA damage in normal as well as malignant tissues. Fur-
thermore preliminary evidence suggests that BRCA1 is
important in the mechanism of action of the spindle poi-
sons paclitaxel and vinorelbine. BRCA1 null tumour cells
may therefore be intrinsically resistant to these agents[21].
BRCA1 and BRCA2 gene carriers are at increased risk of
developing contralateral breast cancer and appear, in the
longer term, to have an increased rate of new primary
tumours in the affected breast (reviewed in[22]). The role
and timing of prophylactic contralateral mastectomy or
bilateral mastectomy in these patients remains uncertain
but the possibility should be considered in this patient
group.
The uncertainties surrounding the most appropriate treat-
ment of breast cancer in BRCA1 and BRCA2 gene carriers
is of critical importance and must be resolved in order that
clinicians can better tailor treatment in hereditary breast
cancer. There is a need for robust unbiased data to provide
clear answers to the question of risk of death from the pre-
senting cancer diagnosis versus risk of a future new pri-
mary cancer in an individual with hereditary breast
cancer. Genotype and tumour phenotype should be con-
sidered so that questions of future risk reducing strategies
can be given appropriate weight and timing by both
patient and the treating oncologist.
We describe here the design and progress of a prospective
study established to provide reliable answers to questions
about the influence of genotype on tumour phenotype
and prognosis.
In addition, since young onset breast cancer is uncom-
mon, the prospective design of this very large cohort study
presents many opportunities for exploring how inherited
genetic traits affect tumour biology and treatment out-
comes. Studies exploring how lower penetrance genes,
radiological features and obesity and weight gain relate to
prognosis in this cohort are some of the sub-studies cur-
rently in progress[23]. The steering group welcomes
expressions of interest for collaborations. The most
important criterion for selecting collaborative projects
will be that the proposed research question can best be
answered in a young onset, symptomatic group of
patients.
Methods/design
The Prospective study of Outcomes in Sporadic versus
Hereditary breast cancer (POSH) is a large, prospective
cohort study. This design was chosen to minimise ascer-
tainment bias, facilitate identification of controls that
could be matched for all potential confounding factors
and ensure accurate standardised and high quality data
collection.BMC Cancer 2007, 7:160 http://www.biomedcentral.com/1471-2407/7/160
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Aims of the study
The primary aims of the study are to determine whether:
(1) The prognosis of patients with breast cancer who har-
bour BRCA1 or BRCA2 gene mutations differs from non
carrier patients after adjustment for age and other major
prognostic indicators.
(2) Breast cancers occurring in patients with an inherited
mutation in the same predisposing gene have a consistent
and distinct tumour phenotype.
(3) There are differences in the pattern of distant breast
cancer recurrence between patients with BRCA1 or BRCA2
gene mutations and matched non carrier patients.
Secondary aims
(1) To develop a validated set of pathological criteria that
improve the specificity and sensitivity of methods for
identifying carriers of germ-line BRCA1/2 mutations to
facilitate future clinical trials based on genotype.
(2) To determine whether inherited genetic variants influ-
ence tumour biology (particularly metastatic potential)
(3) To describe the radiological features in a large cohort
of young breast cancers and correlate these with genetic
factors, tumour pathology and prognosis.
Inclusion criteria
 Women diagnosed with invasive breast cancer
 Aged 40 years or younger at diagnosis
 Diagnosed between January 2000 and December 2007.
Plus
 Women aged 41–50 with a known BRCA1 or BRCA2
gene mutation, diagnosed with invasive breast cancer
within the study period.
Exclusion criteria
 Previous invasive malignancy (with the exception of
non-melanomatous skin cancer)
 Not available for follow up
 Refuse consent to retain diagnostic and follow up data
Ethics Approval
This study received approval from the South and West
Multi-centre Research Ethics Committee (MREC 00/6/69)
Method of recruitment
Study recruitment is supported by the National Cancer
Research Network http://www.ncrn.org.uk/Portfolio/
index.htm. Recruiting centres across England, Scotland,
Wales and Northern Ireland. Recruitment began in April
2001. Recruitment was initially through the Southampton
Breast Centre and all eligible individuals diagnosed from
January 2000 were approached to participate since we
could be sure that there had been no deaths of eligible
women diagnosed between January 2000 and June 2001
when recruiting started in this centre. On joining the
study each new centre was instructed to approach all
patients as early as practical within 12 months of diagno-
sis, to ensure recruitment would be as complete as possi-
ble and not compromised by a failure to recruit patients
who relapse early. Centres were given leave to invite
patients diagnosed over the previous year provided they
could be certain that no potentially eligible patients had
died and could therefore not be invited to participate.
Data collection
All patients giving written informed consent to the study
are asked to complete a short family history and epidemi-
ology questionnaire (additional files 1 and 2). Clinical
data are obtained from the patient medical records by the
Clinical Trials Practitioner (CTP) at each recruiting centre
and entered onto a standard clinical trials data form
(additional file 3). A data form is completed by the CTP at
diagnosis, 6 months, 12 months and then annually from
the date of definitive diagnosis. These forms capture infor-
mation regarding patient characteristics, disease presenta-
tion, diagnosis and treatment, risk reducing surgery, new
primary tumours, recurrence and survival (additional files
3, 4, 5). Annual follow up is continued until death, loss to
follow up or until the end of the active phase of the study
(January 2010).
Copies of all diagnostic breast imaging reports, cytology
and pathology reports and all surgical records are col-
lected to ensure accurate and consistent recording of
tumour characteristics and TNM stage. Tumour pathology
blocks are being collected and will be systematically
reviewed by a panel of study pathologists on completion
of recruitment to the study. Diagnostic mammograms are
being collected and digitised.
Data checking
Study files are randomly selected for periodic checking
against computerised data by the study Principle Investi-
gator (D Eccles) and co-investigator (P Simmonds) to
ensure consistent data entry. The data files for recruits
who die during the period of follow up are systematically
checked for accuracy and consistency of data entry.
¾
¾
¾
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Biological sample banking
A blood sample (30 mls) is collected from each recruit.
Whole blood (for DNA) and serum are stored. Peripheral
Blood Lymphocytes (PBL) are stored of cases where sam-
ple quantity and transit time permit (currently 75% of
cases). Tumour tissue from paraffin blocks is collected
centrally for formal pathology review and assembly of tis-
sue micro arrays.
Genetic risk estimation
A family history questionnaire is completed by each
recruit. Reported diagnoses in the family are accepted as
stated, no attempt is made to verify these diagnoses since
ethical permission was not granted for this. The family
history is used to rank genetic risk for each individual
using the commercially available software Cyrillic® which
implements the BRCAPRO carrier probability algorithm
since this is widely used in genetics services in the UK in
particular[24]. This software does not predict with a high
degree of accuracy the likelihood of BRCA1 or BRCA2 car-
rier status of an individual but uses family history of
breast and ovarian cancer and of unaffected relatives to
derive a "heterozygote risk" (ranging from 1 to 100%)
with probabilities derived from population based segrega-
tion analysis [25]. In a similar way to other commonly
used approaches [26] it provides an objective indication
of the probability of an individual carrying a single auto-
somal dominant high penetrance breast cancer gene
mutation. This software was used since the objective was
to classify patients according to family history using a
ranking system based on number of cancers, type of can-
cer, age at onset and modified by number of unaffected
relatives in the family history. Estimating gene carrier
probabilities is not highly accurate with any currently
available software [27,28]. Mutation testing of BRCA1
and BRCA2 will be carried out in this cohort in the future.
BRCA1 and BRCA2 mutation status is known and
reported at diagnosis for a minority of recruits presenting
before age 41 years (<2%) where prior contact with the
clinical genetics service has allowed predictive testing for
a known familial mutation prior to diagnosis. For the pur-
poses of this analysis, the higher the estimated heterozy-
gote risk, the greater the likelihood that an individual
carries a highly penetrant dominantly inherited gene
mutation. The highest risk group will include the majority
but not all of the BRCA1 and BRCA2 gene carriers in the
cohort. In contrast those falling into the lowest heterozy-
gote risk groups (<20%) are most likely to be sporadic
with minimal genetic component to the risk. The study
criteria were set to ensure that at least 10% of the cohort
will have pathogenic BRCA1 or BRCA2 mutations.
Power calculations
The power estimates depend critically on the prevalence
of mutation carriers. The initial power analyses were
based on a cohort of 2000 patients and looked at a variety
of possible BRCA1 prevalence rates since we intend to
analyse by each gene. In a cohort of 2000 women, if the
prevalence rate of BRCA1 gene carriers is 10%, a study
with 200 BRCA1 gene carriers has 97% power to detect a
difference in 2 year event rate of 20% in gene carriers com-
pared with 10% for sporadic cases. If the prevalence rate
of carriers drops to 5%, the number of carriers would be
100 (estimate for BRCA2) and the power drops to 78% to
detect the same difference in event rates.
Approximately 30% of the participants report some fam-
ily history in first or second degree relatives of breast or
ovarian cancer. Preliminary mutation testing in 120 study
participants revealed 1/38 (3%) of women with no docu-
mented family history of cancer had a pathogenic BRCA1
mutation and 32/81 (39.5%) of recruits with a family his-
tory of breast (or ovarian) cancer had a pathogenic muta-
tion – 22/81 (27%) in BRCA1 and 10/81 (12%) in
BRCA2. The target for recruitment was revised to 3,000 in
2006. From our preliminary mutation testing, we expect
to find 260 BRCA1 gene carriers amongst women present-
ing with a family history (about 30% of the cohort) + 63
BRCA1 gene carriers amongst young women with no fam-
ily history. We would expect 108 BRCA2 gene carriers
amongst the recruits with a family history.
We will in addition have a cohort of know gene carriers
but their treatment choices may differ in light of their
known genetic status. The difficulty of "confounding by
indication" whereby the prognosis partly determines the
choice of treatment, is potentially a significant problem
for non randomised trials such as this [29]. This problem
can be allowed for by careful documentation of the
rationale for particular treatment choices, including pro-
phylactic surgery where this is undertaken. This informa-
tion will be requested at follow up and will allow a more
informative analysis to be made.
Planned statistical analyses
Demographic data and features of the primary tumour
will be compared using the two-sample t-test or the
Mann-Whitney test, as dictated by the distribution of the
response variable. Treatment modalities will be compared
using the chi-squared test. Follow up data will be com-
pared using Kaplan-Meier survival curves, with the log
rank test being used to compare the distribution of recur-
rence-free times. Analysis comparing outcomes for
patients treated differently will be adjusted for patient
characteristics using logistic or Cox regression.
Discussion
In the UK at present most young women diagnosed with
breast cancer have not had a genetic test. Technical chal-
lenges and cost have limited the ability to perform rapidBMC Cancer 2007, 7:160 http://www.biomedcentral.com/1471-2407/7/160
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molecular genetic testing until quite recently. Thus most
newly diagnosed breast cancer cases will be treated on the
basis of tumour prognostic features and without knowl-
edge of the patient's genetic status although family history
is often recorded. As technology moves on and genetic
testing becomes more readily available, treatment deci-
sions may be increasingly influenced by knowledge of the
patient's genetic make-up. At present such genotype
directed management strategies would be premature since
the published evidence is based on inherently unreliable
information from small retrospective studies (reviewed in
[22, 30]). The POSH study will provide unique and
important data about modern breast cancer treatment in
a large group of women with unusually young onset dis-
ease. It will give important insights into the underlying
influences of genetic variation on disease aetiology, host
response to disease and treatment effects as well as long
term outcomes for early onset breast cancer.
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